Patent details

LUC00293 Product Name: Capmatinib or a pharmaceutically acceptable salt thereof

Basic Information

Publication number:
LUC00293
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP078645926
Legal Status:
Inactive
Application number:
LUC00293
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1650
Marketing Authorization Type:
Marketing Authorization Date:
21/06/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
12/12/2022
First Marketing Authorization date:
21/06/2022
Grant date:
04/10/2024
Activation date:
Publication date:
15/12/2022
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
19/11/2032
SPC Extension Expiration:
19/11/2032
Rejection date:
Withdrawal date:

Owner

From:
12/12/2022
 
 

Name:
Incyte Holdings Corporation
Address:
1801 Augustine Cut-Off, Wilmington, DE 19803, United States (US)

Agent

Name:
Dennemeyer & Associates S.A.
From:
12/12/2022
Address:
55, rue des Bruyères, L-1274, HOWALD, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2023/01
Publication date:
03/01/2023
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2024/13
Publication date:
05/11/2024
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
30/11/2027
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
12/12/2022 Application Form 5
12/12/2022 Marketing authorization 3
12/12/2022 Summary of the product caracteristics 36
12/12/2022 MA publication 11
12/12/2022 General Document 3
15/12/2022 Outgoing Correspondence 1
04/10/2024 Publication 1
04/10/2024 Certificate 1
15/12/2022 Publication 1
04/10/2024 Outgoing Correspondence 1